Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Liabilities (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Total Liabilities for 5 consecutive years, with $642.1 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 1.5% year-over-year to $642.1 million; the TTM value through Mar 2026 reached $642.1 million, up 1.5%, while the annual FY2025 figure was $697.3 million, 10.35% up from the prior year.
  • Total Liabilities hit $642.1 million in Q1 2026 for Phathom Pharmaceuticals, down from $697.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $697.3 million in Q4 2025 and bottomed at $111.0 million in Q1 2022.
  • Average Total Liabilities over 5 years is $445.7 million, with a median of $505.0 million recorded in 2024.
  • Year-over-year, Total Liabilities skyrocketed 125.37% in 2024 and then grew 1.5% in 2026.
  • Phathom Pharmaceuticals' Total Liabilities stood at $239.6 million in 2022, then skyrocketed by 103.07% to $486.6 million in 2023, then increased by 29.86% to $631.9 million in 2024, then increased by 10.35% to $697.3 million in 2025, then dropped by 7.92% to $642.1 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $642.1 million, $697.3 million, and $662.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.